Clinical Trial Update: Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated a neoadjuvant regimen combining bevacizumab, everolimus (RAD001), and lapatinib for primary breast cancer. The study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Everolimus (Afinitor) (everolimus)
• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED